Keryx Biopharmaceuticals (NASDAQ: KERX) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Keryx Biopharmaceuticals to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
This table compares Keryx Biopharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Keryx Biopharmaceuticals Competitors||-4,766.77%||-354.87%||-43.42%|
Valuation & Earnings
This table compares Keryx Biopharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Keryx Biopharmaceuticals||$42.83 million||-$121.75 million||-4.17|
|Keryx Biopharmaceuticals Competitors||$464.94 million||$167.77 million||-6.72|
Keryx Biopharmaceuticals’ rivals have higher revenue and earnings than Keryx Biopharmaceuticals. Keryx Biopharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent ratings and recommmendations for Keryx Biopharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Keryx Biopharmaceuticals Competitors||1380||4473||12311||312||2.63|
Keryx Biopharmaceuticals currently has a consensus target price of $7.50, indicating a potential upside of 6.53%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.46%. Given Keryx Biopharmaceuticals’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Keryx Biopharmaceuticals has less favorable growth aspects than its rivals.
Volatility & Risk
Keryx Biopharmaceuticals has a beta of 5.24, indicating that its stock price is 424% more volatile than the S&P 500. Comparatively, Keryx Biopharmaceuticals’ rivals have a beta of 6.57, indicating that their average stock price is 557% more volatile than the S&P 500.
Insider & Institutional Ownership
65.2% of Keryx Biopharmaceuticals shares are held by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.1% of Keryx Biopharmaceuticals shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Keryx Biopharmaceuticals rivals beat Keryx Biopharmaceuticals on 10 of the 12 factors compared.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.